Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02210234 · ClinicalTrials.gov registry record · NA

Wheat Bioactives and Immune Function

A NA study, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
43
Enrollment target

NCT02210234: Completed NA study, sponsored by University of Florida.

NCT02210234 is a NA study that has completed, run by University of Florida. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02210234, a NA study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
43 participants
Enrollment target

Study Summary

The purpose of this research was to understand the effects of bioactive compounds found in wheat cereal on human immunity. Subjects came in for a baseline blood draw, consumed whole wheat bran cereal daily for 21 days, and returned for a final blood draw. Immune function assays were performed at both sampling times. It was predicted that eating wheat bran would benefit immune function.

Primary Outcome

Flow cytometry is used to compare the percentage of γδ-T cells in the total CD3 cell population in the blood of subjects before and after three weeks of consuming whole wheat bran cereal. An increase in that percentage would be suggestive of improved immunity (priming).

Interventions

  • DIETARY_SUPPLEMENT 50 grams of whole wheat bran cereal
  • DIETARY_SUPPLEMENT 100 grams of whole wheat bran cereal

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2010-05
Est. Completion 2010-06
Phase NA
University of Florida

1,106 total trials

What the finished NCT02210234 record still lists

NCT02210234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which 50 grams of whole wheat bran cereal is the first listed.

NCT02210234 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02210234 about?

NCT02210234 is a clinical study titled "Wheat Bioactives and Immune Function". The purpose of this research was to understand the effects of bioactive compounds found in wheat cereal on human immunity. Subjects came in for a baseline blood draw, consumed whole wheat bran cereal daily for 21 days, and returned for a final blood draw. Immune function assays were performed at bot...

What is the current status of trial NCT02210234?

This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2010-05. Estimated completion is 2010-06.

What interventions are being tested in trial NCT02210234?

The interventions under investigation include: 50 grams of whole wheat bran cereal (DIETARY_SUPPLEMENT), 100 grams of whole wheat bran cereal (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02210234?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02210234's enrollment target sits among peer trials

43 1435th of 2000 higher than 565 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02210234, the US trial registry maintained by the National Library of Medicine. NCT02210234 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.